The RNase III endonuclease Dicer plays a key role in generation of microRNAs (miRs). We hypothesized that Dicer regulates cancer cell susceptibility to immune surveillance through miR processing. 
M
icroRNAs (miRs) are 19-to 25-nucleotide noncoding RNA molecules that regulate gene expression at the level of transcription and translation. The RNase III endonuclease Dicer plays a key role in generation of miRs in cells (1) . In cancer, Dicer expression levels have been reported to either positively or inversely correlate with malignant behavior of tumors, depending upon the cancer type (2) (3) (4) , and miRs can act either as oncogenes, as tumor suppressor genes, or sometimes as both (4) (5) (6) . It is therefore important to determine how Dicer and miRs regulate biological properties of cancers. As a way to elucidate the specific impact of Dicer disruption in cancer cells, Vogelstein's group has established human colorectal cancer cell lines in which exon 5 of Dicer gene was disrupted (ex5Ϫ/Ϫ) (7) . Of 97 known miRs detected in wild-type and (ex5Ϫ/Ϫ) HCT116 cells, 55 were differentially expressed, and for 53 of these 55 there was an average 7-fold reduction of miR levels in Dicer (ex5Ϫ/Ϫ) cells compared with wild-type cells. These observations indicate that Dicer is required for the biogenesis of a subset of miRs.
With regard to the roles of Dicer in immune cells, Dicergenerated RNAs appear to be necessary for development of regulatory T cells (8) . Dicer is also required for Type-2 T cell response (9) , which counteracts antitumor immunity (10) . These observations regarding the roles of Dicer in tumor cells and the immune system led us to hypothesize that expression of Dicer in cancer cells might regulate immune surveillance through processing of miRs.
Malignant gliomas, such as glioblastoma multiforme (GBM), represent the most common and aggressive primary brain tumors. Over 12,000 new cases are diagnosed in the United States annually (11) , with a median survival rate of approximately 15 months (12) . Development of novel, molecularly-targeted, multimodal therapeutic approaches is critical to further improve the outcome of these deadly tumors. Recent studies have developed an attractive vehicle for in vivo miR-targeting with the use of antisense ''antagomir'' oligonucleotides (13) . The antagomirmediated silencing of disease-associated miRs may enable development of novel cancer therapies.
Here we demonstrate that Dicer-regulated miRs, miR-222 and miR-339, are expressed in cancer cells, including glioma, and negatively regulate intercellular cell adhesion molecule (ICAM)-1 by direct interaction with its 3Ј UTR. Up-regulation of ICAM-1 expression by inhibition of Dicer or miR-222 or -339 in cancer cells leads to increased susceptibility of cancer cells to antigen-specific cytotoxic T-lymphocytes (CTLs). In primary GBM tissues, expression of Dicer or miR-222 or -339 was inversely associated with ICAM-1 expression. Identification of miRs that affect immune recognition with regulation of ICAM-1 expression has not been previously reported and extends the importance of miRs in inflammation and cancer.
Results

Dicer-Disrupted Cells Exhibit Up-Regulated ICAM-1 Expression and
Enhanced Susceptibility to CTL-Mediated Cytolysis. To evaluate effects of altered Dicer expression status, we obtained 3 human colorectal cancer cell lines HCT116, DLD-1, and RKO, in each of which exon 5 of the human Dicer gene was disrupted (7) . Among them, wild-type HCT116 and HCT116 [ex5Ϫ/Ϫ] cells expressed HLA-A2 as well as the nominal tumor antigens interleukin-13 receptor ␣2 (IL-13R␣2) and EphA2 at similar levels ( Fig. 1B) (14, 15) , allowing us to evaluate HLA-A2-restricted, antigen-specific lytic activity of CTLs against these tumor cells. CTLs were raised against IL-13R␣2 (345-353) or EphA2 (883-891) by in vitro stimulation of HLA-A2ϩ healthy donor-derived peripheral blood mononuclear cells (PBMCs) with the corresponding peptides. As demonstrated in Fig. 1 (16) , demonstrating specificity and activity of the CTL lines. HCT116 (ex5Ϫ/Ϫ) cells were remarkably more susceptible to cytolysis by 2 established CTL lines when compared with wild-type HCT116 cells (Fig. 1 A) . These results suggested that Dicer might regulate expression of molecules that mediate tumor-CTL interaction.
To identify causative molecules that promoted the susceptibility of HCT116 (ex5Ϫ/Ϫ) cells, we examined expression of a panel of proteins that are known to mediate tumor-CTL cell interactions, including HLA class I, ICAM-1, Fas, CD40, DR5, the antigen processing machinery components (␤2 microglobulin, TAP, tapasin, calreticulin, LMP, ERp57, and calnexin) (17) as well as tumor antigens IL-13R␣2 and EphA2 in the ex5Ϫ/Ϫ and wild-type HCT116 cells (Fig. 1B and data not shown) . Among these, ICAM-1 was up-regulated in the ex5Ϫ/Ϫ cells, while none of the other molecules evaluated were differentially expressed in ex5Ϫ/Ϫ vs. wild-type HCT116 cells. Up-regulation of ICAM-1 in ex5Ϫ/Ϫ cells (vs. wild-type cells) was also confirmed in 2 other colorectal cancer cell lines, DLD-1 and RKO (supporting information (SI) Fig. S1 ).
ICAM-1 Promotes Formation of Tumor-CTL Conjugates and Cytolysis of
Dicer (ex5؊/؊) Cells. The binding of lymphocyte function-associated antigen-1 (LFA-1) to its ligand, ICAM-1, is a crucial step in the initial interaction of T-cells (18) during generation of tumor-specific CTL responses (19) . Enhanced ICAM-1 expression on ex5Ϫ/Ϫ vs. wild-type cells suggested increased ability of the CTLs to engage tumor cells. Therefore, we performed conjugate assays to test the hypothesis that ex5Ϫ/Ϫ cells formed more conjugates with the established CTL lines (Fig. 2A) . When ex5Ϫ/Ϫ or wild-type HCT116 cells were labeled with CFSE and incubated with CTLs primed against the IL-13R␣2-or EphA2-derived CTL epitope peptides, HCT116 (ex5Ϫ/Ϫ) cells showed a remarkably higher frequency of conjugate formation with the CTLs compared with that mediated by wild-type HCT116 cells (Fig. 2 A Upper) . Blockade of LFA-1-ICAM-1 interaction using an anti-ICAM-1 monoclonal antibody (mAb) resulted in an apparent inhibition of conjugate formation for both ex5Ϫ/Ϫ and wild-type HCT116 cells (Fig. 2 A  Lower) . Furthermore, blockade of the ICAM-1-LFA-1 interaction by either anti-ICAM-1 or anti-LFA-2 mAb, or by both mAbs, inhibited the specific lysis of the CTLs against HCT116 (ex5Ϫ/Ϫ) cells (Fig. 2B) , indicating a pivotal role of this interaction. Thus, disruption of Dicer in the ex5Ϫ/Ϫ cells confers an enhanced capacity to form stable conjugates with the CTLs through up- regulation of ICAM-1, thereby promoting the susceptibility of ex5Ϫ/Ϫ cells to CTL-mediated lysis.
MiR-222 and -339 Have Predicted Targets in the 3-UTR of ICAM-1
mRNA. We next sought to identify specific miRs that could modulate ICAM-1 expression. Among miRs that were downregulated in HCT116 (ex5Ϫ/Ϫ) cells compared with wild-type HCT116 cells (7), miRs 222 and 339 were predicted to bind to ICAM-1 based on the miRBase algorithm (http://microrna. sanger.ac.uk). Indeed, quantitative RT-PCR analysis showed the decrease of miRs-222 and -339 in all 3 ex5Ϫ/Ϫ cell lines compared with corresponding wild-type cells (Fig. S2 A) . The ''seed'' sequences in miR-222 (5Ј-GCUACA-3Ј, nucleotides 2-7) and -339 (5Ј-CCCUGUCCUCC -3Ј, nucleotides 2-12) matched nucleotides 2067-2072 and nucleotides 1773-1783, respectively, in the human ICAM-1 3Ј-UTR (NM000201) (Fig. S2B ).
SiRNA-Mediated Inhibition of Dicer Suppress miRs-222 and -339 in
Human Malignant Glioma Cells. Development of novel and molecularly targeted therapeutic approaches is critical to improve the outcome of patients with GBM. We next evaluated expression of Dicer and miRs-222 and -339 in human GBM cell lines. A recent study by others (20) and our analysis (shown in Fig. S3 ) suggested expression of Dicer protein in human GBM cell lines, U87, A172, SNB19 and U251. Moreover, 4 GBM cell lines (U87, U251, SNB19, and A172) had elevated expression levels of miRs-222 and -339 when compared to Dicer-disrupted (ex5Ϫ/Ϫ) HCT116 cells (Fig.  3A) . SiRNA-based interference of Dicer significantly inhibited the endogenous levels of miRs-222 and -339 in a glioma cell line U87 (Fig. 3B) . These results suggest that Dicer-mediated regulation of miRs-222 and -339 is not limited to colorectal cancer cells but may represent a general mechanism in other cancers, including GBM.
MiRs-222 and -339 Inhibit ICAM-1 Posttranscriptionally via Direct
Interaction with the ICAM-1 3-UTR. To directly demonstrate that miR-222 and -339 functionally target the 3ЈUTR of ICAM-1 mRNA, we performed luciferase reporter assays. The psiCHECK-2 reporter plasmids contained the ICAM-1 3ЈUTR corresponding to each putative binding site for miR-222 (psiCHECK-2 miR-222 WT) or miR-339 (psiCHECK-2 miR-339 WT) (Fig. S2B ) downstream of renilla luciferase cDNA. We created additional psi-CHECK-2 reporter plasmids, in which mutations were introduced in the putative miR-222 binding site (psiCHECK-2 miR-222 MT) or the putative miR-339 binding site (psiCHECK-2 miR-339 MT) (see Materials and Methods). Each of these psiCHECK-2 vectors or a control luciferase vector without the 3ЈUTR (psiCHECK-2) was cotransfected into U87 cells with miR-222 or -339 precursor (premiR). Ectopic expression of premiR-222 inhibited the relative luciferase activity in U87 cells transfected with psiCHECK-2 miR-222 WT as compared with the control premiR-transfected cells ( Fig. 4A Left and Fig. S4A ), but had no effects on U87 cells transfected with psiCHECK-2 miR-222 MT. Transfection of premiR-339 decreased the relative luciferase activity in U87 cells transfected with psiCHECK-2 miR-339 WT as compared with the control premiR-transfected cells but had no effects on U87 cells transfected with the control luciferase vector or psiCHECK-2 miR-339 MT (Fig. 4A Right and Fig. S4A) .
We predicted that miRs-222 and -339 would down-regulate ICAM-1 expression at the level of translation, because ICAM-1 does not contain an exact match to either miR-222 or miR-339 in its 3Ј-UTR (Fig. S2B) . To corroborate this prediction, we measured ICAM-1 mRNA expression levels in U87 cells transfected with Dicer siRNA or premiRs. Neither premiR-222, premiR-339, nor Dicer siRNA altered the ICAM-1 mRNA expression in these cells (Fig. 4B) . These data suggest that miR-222 and -339 down-regulate ICAM-1 expression at posttranscriptional levels by binding to the ICAM-1 3ЈUTR.
Inhibition of miRs-222 or -339 Leads to Recovery of ICAM-1 Expression in Human Malignant Glioma Cells and Promotes Their Susceptibility to
CTL-Mediated Cytolysis. We next assessed the effect of Dicer and miRs-222 and -339 on ICAM-1 expression. U87 GBM cells were transfected with Dicer siRNA, precursors, or inhibitors for the miRs, or appropriate control constructs. Cell surface ICAM-1 expression on the transfectants was quantified by flow-cytometric analyses (Fig. 5A and Fig. S5A) , and the total expression in whole cell lysates was measured by immunoblotting ( Fig. 5B and Fig. S5B ). U87 cells transfected with Dicer siRNA showed increased ICAM-1 expression when compared to control RNA duplex-transfected cells ( To determine the functional relevance of Dicer and miRs-222 and -339 to CTL-mediated antitumor effects, we performed CTL assays using these genetically engineered U87 cells as target cells for CTLs raised against EphA2 (883-891) epitope. Inhibition of Dicer and antagonism of either miRNA-222 or -339 in HLA-A2 ϩ U87 cells significantly enhanced their susceptibility to the CTLs compared with relevant control groups (Fig. 5C) . Moreover, blockade of ICAM-1 with a specific antibody restrained the susceptibility of these genetically engineered U87 cells. These results indicate that the Dicer-regulated miRs-222 and -339 target ICAM-1, leading to enhanced CTL-mediated antitumor effects.
Expression of Dicer and miR-222 and miR-339 Was Inversely Associated
with ICAM-1 Expression in Primary GBM Tissues. These results with in vitro cultured cells led us to hypothesize that the status of Dicer and the miR expression might inversely correlate with ICAM-1 expression in primary GBM tissues. We performed in situ hybridization of miR-222 and -339, and immunohistochemical analyses on Dicer and ICAM-1 in 30 primary GBM tissues. Table 1 summarizes degrees of miR-222/339 expression and Dicer/ICAM-1 immunopositivity in these cases, and Fig. 6 demonstrates miR expression and Dicer/ICAM-1 staining in 4 cases (GB 2, 20, 25, and 26) as examples. Dicer staining and expression of miR-222 or miR-339 were inversely associated with ICAM-1 staining, with Spearman's correlation coefficients of Ϫ0.452 (P ϭ 0.013), Ϫ0.532 (P ϭ 0.004) and Ϫ0.427 (P ϭ 0.021), respectively. A positive correlation coefficient between miR-222 expression (r ϭ 0.388, P ϭ 0.037) or miR-339 expression (r ϭ 0.385, P ϭ 0.038) and Dicer immunopositivity was observed. These data support our hypothesis that Dicer and Dicermediated miRs may have a role in regulation of ICAM-1 in vivo.
Discussion
This is the first report on roles of miRs-222 and -339 in regulation of ICAM-1 at posttranscriptional levels. MiR-regulated ICAM-1 mediates cancer cells' susceptibility to CTLs, and levels of Dicer and miR-222 and -339 are inversely associated with ICAM-1 expression not only in vitro cultured cells but also in primary GBM tissues. The significance of Dicer expression levels on prognosis of cancer patients is still controversial (2, 3, 6) . Because miRs can act either as oncogenes, as tumor suppressor genes, or sometimes as both (5), alteration of Dicer levels can probably influence the malignant behavior of cancers either positively or negatively depending upon the profiles of miR expression status in each cancer type. In the current study with primary GBM tissues, Dicer was expressed at varying levels, and it would be intriguing to know whether Dicer expression in GBM correlates with prognosis of patients. Interestingly, miR let-7, whose reduced expression was associated with shorter patient survival (4), inhibits Dicer expression by directly targeting the 3Ј UTR of Dicer (21) . Therefore, let-7 serves as a prototypic ''tumor-suppressor-miR,'' functioning as a key microRNA in a novel regulatory loop limiting Dicer expression. Although recent studies have suggested a general down-regulation of miRs in tumors compared with normal tissues (22, 23) , these studies also stress the significance of miR-profiling for dictating tumor-tissue origins and differentiation status.
There are groups of miRs that are known to be overexpressed in solid cancers. Some of these miRs, such as miR-17-5p, miR-20a, miR-21, miR-92, miR-106a, and miR-155, are well characterized for their biological properties contributing to malignant behavior (24) . With regard to miR-222 and -339 in cancers, miR-221 and -222 are up-regulated in human thyroid papillary carcinomas in comparison with normal thyroid tissue (25) . miR-221 and -222 directly target the p27(Kip1) protein, a key regulator of cell cycle, thereby inducing progression to the S phase of the cell cycle (25) . Although cell-cycle analysis was not within the scope of our current study, it would be intriguing to address whether modulation of Dicer and miR-222 can influence the proliferation of colon cancer and glioma cells. A more recent study with melanoma has identified c-KIT receptor as another target of overexpressed miR-222, leading to blockade of differentiation in melanoma cells (26) . In GBMs, up-regulation of miR-222/221 has been reported (20, 27, 28) , as well as miR-21 (27, 29) . Since miR-221 was not predicted to bind to ICAM-1, we did not evaluate miR-221 in the current study. Taken together, information from recent studies suggests miR-222 may be a suitable therapeutic target to suppress the proliferation of poorly-differentiated tumor cells, and to enhance immunoreactivity against CTL-based immunotherapy. There is paucity of information in the literature regarding the roles of miR-339 in neoplastic cells. Further studies are warranted to determine additional roles of miR-339 in neoplasms.
Our data indicated that ICAM-1 has a pivotal role in physical and functional interaction between tumor cells and CTLs. The binding of LFA-1 to its ligand, ICAM-1, is a crucial step in the migration of leukocytes and T cell activation (18) . ICAM-1/ LFA-1 interaction is required to generate tumor-specific CTL responses (19) . These observations suggest that the reduced expression of ICAM-1 on tumor cells could prevent efficient association of CTLs to tumor cells, contributing, at least partially, to tumor escape from the host immune surveillance. Indeed, reduced expression of ICAM-1 is associated with poor prognosis in various cancers, such as melanoma (30) and head and neck (31) , breast (32) , colorectal (33) , and ovarian cancers (34) . These previous studies also point to the significance of identifying miRs that regulate ICAM-1. Further studies are warranted to determine the possible predictive value of ICAM-1 on prognosis of patients with GBM.
It has been implicated that the ICAM-1/LFA-1 interaction also stimulates NK cells' cytotoxic activity (35) . Accordingly, in our preliminary data (Fig. S6) , Dicer (ex 5Ϫ/Ϫ) cells exhibited greater sensitivity to NK cell-mediated lysis. However, a recent study indicated that inhibition of Dicer leads to up-regulation of ligands for the NKG2D receptor, MICA, and MICB via DNA damage (36) . Hence, a variety of immunological mechanisms may operate in increased susceptibility of Dicer (ex5 Ϫ/Ϫ) cells against immune surveillance.
Recent studies have developed an attractive vehicle for in vivo miR-targeting by the use of antisense ''antagomir'' oligonucleotides (13) . Based on the present study, targeted therapies suppressing miR-222 and -339 may prove beneficial in cancers and cancer immunotherapy.
Materials and Methods
Cell lines, antibodies, peptides, and Flow cytometric analyses (See SI Text).
Patients and Samples. This study was approved by the local ethical review board of University of Pittsburgh. Frozen GBM tissues were obtained from the *0, negative staining; ϩ1, weakly positive staining; ϩ2, moderately positive staining; ϩ3, strongly positive at focal areas; ϩ4, strongly and diffusely positive throughout the lesion. In Vitro Induction of CTL in PBMCs and Cytotoxicity Assay. CTL induction and 51 Cr release cytotoxicity assay were performed as previously described (37) and detailed in SI Text.
Conjugate Assay. Conjugate assays were performed as described in SI Text.
MiR and mRNA Real-Time Quantitative RT-PCR Analysis. TRIzol-extracted (Invitrogen), DNase I-treated total RNA (10 ng) was subjected to qRT-PCR analysis using the TaqMan miR Reverse Transcription Kit and miR Assays (Applied Biosystems), and the Real-Time thermocycler iQ5 (Bio-Rad). The small nucleolar RNU43 was used as the housekeeping small RNA reference gene. All reactions were done in triplicate and relative expression of RNAs was calculated using the 2 ⌬C T method (38) . QRT-PCR analysis of ICAM-1 mRNA was performed as detailed in SI Text.
Dicer RNA Interference, Inhibition of Endogenous miRs, and Ectopic Expression of PremiRs. We used a synthetic RNA duplex with the sense strand sequences CACUGGUCAGGGAAGACAUU (Dicer siRNA) (20) for Dicer RNA interference and Scrambled II duplex (39) as a control duplex, both of which were purchased from Dharmacon. MiRs-222 or -339 were expressed in cell lines by transfection with a premiR precursor molecule (premiR) (Ambion) and inhibited with miR inhibitor (miR inhibitor) (Ambion). Amaxa Nucleofector technology was used for transfection according to the manufacturer's instructions. Cells were seeded (5 ϫ 10 5 /well) into 6-well plates and were harvested after 20 h, and RNA and protein extractions were performed.
Luciferase Activity Assay. U87 cells were cotransfected with premiRs or miR inhibitors and 2 g of renilla/firefly luciferase reporter plasmid as described in SI Text. Cells were harvested 24 h later for analysis of luciferase activity. Luciferase assays were performed using the Dual Luciferase Assay System (Promega) according to the manufacturer's instructions. Relative luciferase activity was obtained by normalizing the renilla luciferase activity to the firefly luciferase activity.
Western Blotting. Western blot was performed as previously described (40) and detailed in SI Text.
Immunohistochemical Staining and Scoring Staining. Immunohistochemistry was done as previously described (37) and detailed in SI Text.
Locked Nucleic Acid-Based in Situ Detection of miRs in Primary GBM Tissues. In situ hybridizations were performed in 12-m cryosections from primary GBM tissues as previously described (41) 
